BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 19342367)

  • 1. MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus.
    Maru DM; Singh RR; Hannah C; Albarracin CT; Li YX; Abraham R; Romans AM; Yao H; Luthra MG; Anandasabapathy S; Swisher SG; Hofstetter WL; Rashid A; Luthra R
    Am J Pathol; 2009 May; 174(5):1940-8. PubMed ID: 19342367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma.
    Yang H; Gu J; Wang KK; Zhang W; Xing J; Chen Z; Ajani JA; Wu X
    Clin Cancer Res; 2009 Sep; 15(18):5744-52. PubMed ID: 19737949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma.
    Wu X; Ajani JA; Gu J; Chang DW; Tan W; Hildebrandt MA; Huang M; Wang KK; Hawk E
    Cancer Prev Res (Phila); 2013 Mar; 6(3):196-205. PubMed ID: 23466817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorescence in situ hybridization mapping of esophagectomy specimens from patients with Barrett's esophagus with high-grade dysplasia or adenocarcinoma.
    Brankley SM; Fritcher EG; Smyrk TC; Keeney ME; Campion MB; Voss JS; Clayton AC; Wang KK; Lutzke LS; Kipp BR; Halling KC
    Hum Pathol; 2012 Feb; 43(2):172-9. PubMed ID: 21820152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic changes in microRNA expression profiles reflect progression of Barrett's esophagus to esophageal adenocarcinoma.
    Slaby O; Srovnal J; Radova L; Gregar J; Juracek J; Luzna P; Svoboda M; Hajduch M; Ehrmann J
    Carcinogenesis; 2015 May; 36(5):521-7. PubMed ID: 25784377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Large intra- and inter-individual variability of genes expression levels limits potential predictive value of molecular diagnosis of dysplasia in Barrett's esophagus.
    Hennig EE; Mikula M; Orlowska J; Jarosz D; Bielasik A; Regula J; Ostrowski J
    J Mol Med (Berl); 2008 Feb; 86(2):233-42. PubMed ID: 17952395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.
    Kimchi ET; Posner MC; Park JO; Darga TE; Kocherginsky M; Karrison T; Hart J; Smith KD; Mezhir JJ; Weichselbaum RR; Khodarev NN
    Cancer Res; 2005 Apr; 65(8):3146-54. PubMed ID: 15833844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes of microRNAs-192, 196a and 203 correlate with Barrett's esophagus diagnosis and its progression compared to normal healthy individuals.
    Luzna P; Gregar J; Uberall I; Radova L; Prochazka V; Ehrmann J
    Diagn Pathol; 2011 Nov; 6():114. PubMed ID: 22094011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence.
    Lord RV; Salonga D; Danenberg KD; Peters JH; DeMeester TR; Park JM; Johansson J; Skinner KA; Chandrasoma P; DeMeester SR; Bremner CG; Tsai PI; Danenberg PV
    J Gastrointest Surg; 2000; 4(2):135-42. PubMed ID: 10675236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
    Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
    Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TGR5 expression in benign, preneoplastic and neoplastic lesions of Barrett's esophagus: Case series and findings.
    Marketkar S; Li D; Yang D; Cao W
    World J Gastroenterol; 2017 Feb; 23(8):1338-1344. PubMed ID: 28293080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The diagnosis and management of Barrett's esophagus.
    DeMeester SR; DeMeester TR
    Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
    Lord RV; Brabender J; Wickramasinghe K; DeMeester SR; Holscher A; Schneider PM; Danenberg PV; DeMeester TR
    Surgery; 2005 Nov; 138(5):924-31. PubMed ID: 16291394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential MicroRNA Signatures in the Pathogenesis of Barrett's Esophagus.
    Craig MP; Rajakaruna S; Paliy O; Sajjad M; Madhavan S; Reddy N; Zhang J; Bottomley M; Agrawal S; Kadakia MP
    Clin Transl Gastroenterol; 2020 Jan; 11(1):e00125. PubMed ID: 31934893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA profile in neosquamous esophageal mucosa following ablation of Barrett's esophagus.
    Sreedharan L; Mayne GC; Watson DI; Bright T; Lord RV; Ansar A; Wang T; Kist J; Astill DS; Hussey DJ
    World J Gastroenterol; 2017 Aug; 23(30):5508-5518. PubMed ID: 28852310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The microRNAs, MiR-31 and MiR-375, as candidate markers in Barrett's esophageal carcinogenesis.
    Leidner RS; Ravi L; Leahy P; Chen Y; Bednarchik B; Streppel M; Canto M; Wang JS; Maitra A; Willis J; Markowitz SD; Barnholtz-Sloan J; Adams MD; Chak A; Guda K
    Genes Chromosomes Cancer; 2012 May; 51(5):473-9. PubMed ID: 22302717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus.
    Brabender J; Marjoram P; Salonga D; Metzger R; Schneider PM; Park JM; Schneider S; Hölscher AH; Yin J; Meltzer SJ; Danenberg KD; Danenberg PV; Lord RV
    Oncogene; 2004 Jun; 23(27):4780-8. PubMed ID: 15107828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glutathione S-transferase-pi expression is downregulated in patients with Barrett's esophagus and esophageal adenocarcinoma.
    Brabender J; Lord RV; Wickramasinghe K; Metzger R; Schneider PM; Park JM; Hölscher AH; DeMeester TR; Danenberg KD; Danenberg PV
    J Gastrointest Surg; 2002; 6(3):359-67. PubMed ID: 12022988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LOH at the sites of the DCC, APC, and TP53 tumor suppressor genes occurs in Barrett's metaplasia and dysplasia adjacent to adenocarcinoma of the esophagus.
    Dolan K; Garde J; Walker SJ; Sutton R; Gosney J; Field JK
    Hum Pathol; 1999 Dec; 30(12):1508-14. PubMed ID: 10667431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in mitochondrial stability during the progression of the Barrett's esophagus disease sequence.
    O'Farrell NJ; Feighery R; Picardo SL; Lynam-Lennon N; Biniecka M; McGarrigle SA; Phelan JJ; MacCarthy F; O'Toole D; Fox EJ; Ravi N; Reynolds JV; O'Sullivan J
    BMC Cancer; 2016 Jul; 16():497. PubMed ID: 27431913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.